Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia by Helbig, Grzegorz et al.
LETTER TO THE EDITOR
Durable remission after treatment with very low doses of imatinib
for FIP1L1-PDGFRa-positive chronic eosinophilic leukaemia
Grzegorz Helbig • Andrzej Moskwa • Marek Hus • Jarosław Piszcz •
Alina Swiderska • Alina Urbanowicz • Małgorzata Całbecka • Ilona Seferyn ´ska •
Małgorzata Raz ´ny • Marek Rodzaj • Ewa _ Zuk • Sławomira Kyrcz-Krzemien ´
Received: 25 September 2010/Accepted: 31 January 2011/Published online: 17 February 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
To the Editor,
The exquisite response to imatinib mesylate in patients
with chronic eosinophilic leukaemia (CEL) harbouring the
FIP1L1-PDGFRa (F/P) fusion transcript has been well
documented [1–4]. In the up-to-date largest multicentre
study, all 27 patients with detectable F/P mutation achieved
complete haematological and molecular remission after
imatinib therapy and have remained in continuous remis-
sion after median of 25 months [2].
The initial daily doses of imatinib ranged from 100 to
400 mg in a majority of published reports, but maintained
imatinib doses were not fully established [2, 5]. It was also
demonstrated that imatinib dose reduction or temporary
discontinuation was associated with molecular and clinical
relapse [6, 7]. Additionally, single cases of imatinib-
resistant F/P-positive CEL have been reported [8].
As the response rate after imatinib is close to 100%, the
current issue is (1) to establish a minimal effective imatinib
dose needed to remission maintenance and (2) to evaluate
the duration of imatinib response.
Recently, we reported on high efﬁcacy of weekly
imatinib schedule in 13 F/P-positive CEL patients. Imatinib
at weekly dosage seemed to be sufﬁcient to maintain
haematological and molecular remission with a median of
21 months of follow-up in this studied subgroup [9].
Herein, we present long-term results of F/P-positive
CEL after imatinib. The data were collected from ten
centres in Poland. All patients gave written informed
consent. Twenty male and two female patients at median
age of 52 years (range 22–80 years) were included in this
partially retrospective study. Organ involvement was
demonstrated in 91% of patients, and splenomegaly was
the most common clinical manifestation. At diagnosis,
23% of patients were asymptomatic. Median blood
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tion were 12 9 10
9/l (range 2.5–40) and 39.5% (range
7.0–80), respectively. The starting, de-escalated and
maintained imatinib doses were left to the physician’s
discretion. The initial imatinib doses were as follows:
100 mg/day (n = 18), 400 mg/day (n = 3) and 300 mg/
day (n = 1). All treated patients achieved haematological
remission after median of 13 days (range 3–90). Complete
molecular remission by nested RT-PCR was conﬁrmed
after median of 10 months (range 3–24). They became free
of symptoms. The maintained imatinib doses were fol-
lowing: 100 mg per week (n = 11), 200 mg per week
(n = 2), 400 mg per week (n = 1), 100 mg twice a week
(n = 2), 100 mg thrice a week (n = 2) and 100 mg a day
(n = 4). Imatinib doses and duration of treatment were
shown in Table 1. All studied patients remained in com-
plete haematological and molecular remission after median
follow-up of 41 months (range 11–71). Median time at
maintained imatinib doses was 27 months (range 2–61).
Imatinib plasma levels were measured using high-perfor-
mance liquid chromatography-tandem mass spectrometry
method [10]. Blood samples were taken 24 h after the last
imatinib intake from eleven patients: from 9 patients on
100 mg weekly imatinib and from 2 on imatinib at 200 mg
a week. Imatinib plasma levels appeared to be extremely
low and ranged between 44 and 164 ng/ml and
103–203 ng/ml, respectively, for both analysed groups. Of
note is that F/P negativity was conﬁrmed at the same time
points by nested RT-PCR.
With this large series of F/P-positive CEL patients, we
can conﬁrm that imatinib may induce durable remission
with the maximum follow-up of 71 months until last
contact. Most recently, Rondoni et al. [11] presented the
follow-up results of 33 F/P-positive CEL patients on
imatinib with a continuous remission after median of
51 months (range 30–92). In contrary to our report, the
maintained imatinib doses were 100 mg a day. It is
noteworthy that 18 patients from our study group
received imatinib at total maintained doses of 400 mg a
week or less. We have proved that treatment with such
low imatinib doses may maintain molecular remission
despite low imatinib plasma levels. Nevertheless, the
longer follow-up is needed to conﬁrm our encouraging
results.
Table 1 Imatinib doses and duration of therapy in F/P-positive CEL patients
Patients Starting imatinib
dose (mg/day)
First de-escalated
imatinib dose (mg)
Maintained
imatinib dose
(mg)
Plasma imatinib
level at maintained
imatinib dose (ng/ml)
Months on
maintained
imatinib dose
Total time
on imatinib
(months)
Patient 1 100 200 per week 100 per week 46 54 67
Patient 2 100 200 per week 100 per week 47 61 66
Patient 3 400 400 per week 100 per week 44 3 12
Patient 4 100 100 BIW 100 per week 125 18 54
Patient 5 100 100 per week 100 per week 24 34 37
Patient 6 100 100 per week 100 per week 67 31 40
Patient 7 100 100 per week 100 per week 99 29 30
Patient 8 100 100 per week 100 per week 164 56 58
Patient 9 100 100 BIW 100 per week 123 8 17
Patient 10 100 100 per week 100 per week ND 15 51
Patient 11 100 100 per week 100 per week ND 16 19
Patient 12 400 100 daily 200 per week ND 41 63
Patient 13 400 100 daily 200 per week ND 43 45
Patient 14 100 100 BIW 100 BIW 103 27 28
Patient 15 100 100 BIW 100 BIW 203 4 14
Patient 16 100 100 TIW 100 TIW ND 16 64
Patient 17 100 100 TIW 100 TIW ND 11 71
Patient 18 100 100 BIW 400 per week ND 2 39
Patient 19 100 NA 100 daily ND NA 50
Patient 20 100 NA 100 daily ND NA 37
Patient 21 100 NA 100 daily ND NA 11
Patient 22 300 100 daily 100 daily ND 40 41
BIW twice a week, TIW thrice a week, ND not done, NA not applicable
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